{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:38:04Z","timestamp":1773812284739,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12941-017-0178-0","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T11:36:14Z","timestamp":1484652974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system"],"prefix":"10.1186","volume":"16","author":[{"given":"Islam M.","family":"Ghazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Grupper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"178_CR1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1975.tb01444.x","volume":"15","author":"MI Marks","year":"1975","unstructured":"Marks MI. In vitro antibacterial activity of amikacin, a new aminoglycoside, against clinical bacterial isolates from children. J Clin Pharmacol. 1975;15:246\u201351.","journal-title":"J Clin Pharmacol"},{"key":"178_CR2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/AAC.31.7.1126","volume":"31","author":"A Favero Del","year":"1987","unstructured":"Del Favero A, Menichetti F, Guerciolini R, Bucaneve G, Baldelli F, Aversa F, et al. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrob Agents Chemother. 1987;31:1126\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"178_CR3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/518460","volume":"28","author":"DJ Weber","year":"2007","unstructured":"Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28:825\u201331.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"178_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17434440.5.1.9","volume":"5","author":"R Dhand","year":"2008","unstructured":"Dhand R, Sohal H. Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices. 2008;5:9\u201318.","journal-title":"Expert Rev Med Devices"},{"key":"178_CR5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jac\/dkv370","volume":"71","author":"W So","year":"2016","unstructured":"So W, Crandon JL, Hamada Y, Nicolau DP. Antibacterial activity of achievable epithelial lining fluid exposures of amikacin inhale with or without meropenem. J Antimicrob Chemother. 2016;71:428\u201337.","journal-title":"J Antimicrob Chemother"},{"key":"178_CR6","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1186\/cc8206","volume":"13","author":"CE Luyt","year":"2016","unstructured":"Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2016;13:R200.","journal-title":"Crit Care"},{"key":"178_CR7","volume-title":"Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement [document M100-S25]","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement [document M100-S25]. Wayne: National Committee for Clinical Laboratory Standards; 2015."},{"key":"178_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijantimicag.2014.05.012","volume":"44","author":"ST Housman","year":"2014","unstructured":"Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014;44:235\u201341.","journal-title":"Int J Antimicrob Agents"},{"key":"178_CR9","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1128\/AAC.04839-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother. 2015;59:3263\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"178_CR10","doi-asserted-by":"crossref","unstructured":"Stass H, Willmann S, Wendl T. Risk assessment for amikacin inhale in ICU patients using whole-body physiologically based PK-models. Poster 926. Society of critical care medicine (SCCM) 43rd critical care congress. San Francisco; 2014.","DOI":"10.1097\/01.ccm.0000440164.10739.1d"},{"key":"178_CR11","first-page":"349","volume":"31","author":"J Blaser","year":"1987","unstructured":"Blaser J, Zinner SH. In vitro models for the study of antibiotics activities. Prog Drug Res. 1987;31:349\u201381.","journal-title":"Prog Drug Res"},{"key":"178_CR12","first-page":"153","volume":"25","author":"G Zhanel","year":"1991","unstructured":"Zhanel G, Hoban D, Harding G. The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother. 1991;25:153\u201363.","journal-title":"DICP Ann Pharmacother."},{"key":"178_CR13","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/AAC.42.7.1842","volume":"4","author":"AD Kashuba","year":"1998","unstructured":"Kashuba AD, Bertino JS Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother. 1998;4:1842\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"178_CR14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jama.1971.03180210043008","volume":"215","author":"F Richards","year":"1971","unstructured":"Richards F, McCall C, Cox C. Gentamicin treatment of staphylococcal infections. JAMA. 1971;215:1297\u2013300.","journal-title":"JAMA"},{"key":"178_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3947\/ic.2013.45.1.62","volume":"45","author":"JH Hwang","year":"2013","unstructured":"Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study. Infect Chemother. 2013;45:62\u20138.","journal-title":"Infect Chemother."},{"key":"178_CR16","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1128\/AAC.00778-13","volume":"57","author":"R Schwameis","year":"2013","unstructured":"Schwameis R, Erdogan-Yildirim Z, Manafi M, Zeitlinger MA, Strommer S, Sauermann R. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother. 2013;57:5151\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"178_CR17","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149\u201352.","journal-title":"J Infect Dis"},{"key":"178_CR18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.39.2.329","volume":"39","author":"A Veen van \u2018t","year":"1995","unstructured":"van \u2018t Veen A, Mouton JW, Gommers D, Kluytmans JA, Dekkers P, Lachmann B. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother. 1995;39:329\u201333.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-017-0178-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:05:34Z","timestamp":1568739934000},"score":1,"resource":{"primary":{"URL":"http:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-017-0178-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1186\/s12941-017-0178-0","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]},"article-number":"2"}}